Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model

Abstract

AimsAbiraterone treatment requires regular drug intake under fasting conditions due to pronounced food effect, which may impact patient adherence. The aim of this prospective study was to evaluate adherence to abiraterone treatment in patients with prostate cancer. To achieve this aim, an abiraterone population pharmacokinetic model was developed and patients' adherence has been estimated by comparison of measured levels of abiraterone with population model‐based simulations.MethodsA total of 1469 abiraterone plasma levels from 83 healthy volunteers collected in a bioequivalence study were analysed using a nonlinear mixed‐effects model. Monte Carlo simulation was used to describe the theoretical distribution of abiraterone pharmacokinetic profiles at a dose of 1000 mg once daily. Adherence of 36 prostate cancer patients treated with abiraterone was then evaluated by comparing the real abiraterone concentration measured in each patient during follow‐up visit with the theoretical distribution of profiles based on simulations. Patients whose abiraterone levels were ˂5th or ˃95th percentile of the distribution of simulated profiles were considered to be non‐adherent.ResultsBased on this evaluation, 13 patients (36%) have been classified as non‐adherent. We observed significant association (P = .0361) between richness of the breakfast and rate of non‐adherence. Adherent patients reported significantly better overall condition in self‐assessments (P = .0384). A trend towards a higher occurrence of adverse effects in non‐adherent patients was observed.ConclusionsWe developed an abiraterone population pharmacokinetic model and proposed an advanced approach to medical adherence evaluation. Due to the need for administration under fasting conditions, abiraterone therapy is associated with a relatively high rate of non‐adherence.